TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 1.3% – Should You Sell?

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s stock price fell 1.3% on Tuesday . The company traded as low as $2.21 and last traded at $2.21. Approximately 154,149 shares changed hands during trading, a decline of 76% from the average daily volume of 637,012 shares. The stock had previously closed at $2.24.

Analyst Ratings Changes

A number of research analysts have commented on HURA shares. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Rodman & Renshaw started coverage on TuHURA Biosciences in a report on Wednesday, April 15th. They set a “buy” rating on the stock. Citigroup began coverage on TuHURA Biosciences in a research report on Monday, April 27th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Stock Performance

The firm has a market capitalization of $138.19 million, a price-to-earnings ratio of -3.56 and a beta of -0.05. The firm has a fifty day moving average price of $2.33 and a 200 day moving average price of $1.83.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Research analysts predict that TuHURA Biosciences, Inc. will post -0.56 earnings per share for the current fiscal year.

Institutional Trading of TuHURA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Merck & Co. Inc. increased its holdings in TuHURA Biosciences by 39.4% in the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock valued at $35,000 after buying an additional 5,495 shares in the last quarter. PFG Investments LLC lifted its position in shares of TuHURA Biosciences by 39.4% during the 1st quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock valued at $58,000 after acquiring an additional 9,219 shares during the period. Virtu Financial LLC purchased a new stake in shares of TuHURA Biosciences during the 3rd quarter worth approximately $26,000. JPMorgan Chase & Co. purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $27,000. Finally, Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.